Lumpy skin disease in the EU

13th REMESA JPC (Byblos, Lebanon, 3-4 November 2016)

Dr Moritz KLEMM
European Commission
Directorate-General for Health and Food Safety
G2 – Animal Health and Welfare
LSD, the disease

- **Causative agent**: Capripoxvirus
- Affects cattle & buffaloes (some exotic wildlife too?)
- Transmitted mostly by blood feeding insects (other direct–indirect routes possible but less common)
- Signs include fever, skin nodules
- Mortality usually not very high but may cause serious economic losses (production drops) especially when introduced into a naive population.
- Control measures: mass vaccination + stamping out + zoning
LSD global evolution
Lumpy Skin Disease, 2005 - 2013

Source: EFSA Journal 2015;13(1):3986, EFSA opinion on LSD, Jan 2015, info from OIE
Recent spread of LSD*

*OIE Data as at 12.9.2016

Info presented at the GF-TADs SGE LSD2 (21 Sep 2016, Lisbon, Portugal)
LSD in the EU
LSD situation in 2013 - 2015

Disease spread

May 2015 (Reported in June)

Nov - Dec 2014, in the areas not under the effective control of the Government of the Republic of Cyprus
Lumpy Skin Disease outbreaks in 2015

(Aug-Dec 2015)

- 1st Occurrence in continental Europe (Greece, 117 outbreaks)
LSD situation in 2015: Greece (Aug-Dec 2015)

South Evros (Aug 2015)
1st Occurrence of LSD in Greece

LSD restricted/vaccinated area

Bulgaria

FYROM

Xanthi (Late Sept. 2015)
Kavala (Early Oct. 2015)
Rodopi (Mid Oct. 2015)
Northern Evros (Mid Sept. 2015)

Greece

Chalkidiki (Mid Oct. 2015)

Thessaloniki (Nov. 2015)

Limnos (Early Oct. 2015)
Lumpy Skin Disease outbreaks in 2016

(April 2016)

- Recurrence in Greece
- 1st Occurrence in Bulgaria and the former Yugoslav Republic of Macedonia
Lumpy Skin Disease outbreaks in 2016

(May 2016)
Lumpy Skin Disease outbreaks in 2016

(June 2016)

- 1st Occurrence in Serbia and Kosovo*

*This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence.
Lumpy Skin Disease outbreaks in 2016

(July 2016)

- 1st Occurrence in Albania and Montenegro
Lumpy Skin Disease outbreaks in 2016

(August 2016)
Lumpy Skin Disease outbreaks in 2016

(September 2016)
LSD epidemiological situation January to early October 2016 (ADNS + country reports)

LSD outbreaks in SE Europe (April – early Oct 2016)

- **Greece**: 100
  (last on 3/10/2016)

- **Bulgaria**: 217
  (last on 1/8/2016)

- **FYROM**: 1591 (Sep report)

- **Serbia**: 221
  (last on 3/09/2016)

- **Kosovo**: 76 (Aug report)

- **Montenegro**: > 400

- **Albania**: 1516 (Sep report)

(*) This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo Declaration of Independence.

LSD outbreaks 2016 (ADNS)
LSD outbreaks in the South East Europe in 2016 as recorded in ADNS
(Number of new LSD outbreaks reported in ADNS every 2 weeks by confirmation date in April – Early Oct 2016)
Lumpy Skin Disease recent Activities (2015 – mid 2016)


Update regarding the Standing Group of Experts on LSD

New initiative building on the positive SGE experience for ASF

SGE LSD

Launching

SGE LSD1, Brussels, 4-5 July 2016)

Presidency and Secretariat

Countries with an institutional role

South East Europe (19 countries)

Affected and at-risk countries

Update

SGE LSD2, Lisbon, 22 Sept 2016)
Update regarding the Standing Group of Experts on LSD

**Latest developments?**

- **Specific capacity building activities**
  - **BTSF Regional Training Workshops** (Greece Nov 2015; series of seminars April, June, Oct 2016)
  - **Sustained Training Missions** (Montenegro, Bosnia & Herzegovina)
  - **CVET missions** (Cyprus, Greece, Serbia, FYROM, Romania), all contributing to the objectives of the SGE LSD

**Next?**

- **Third meeting of the Standing Group of Expert on LSD** (SGE LSD3, Istanbul, Turkey, 12-13 Dec 2016)
Regional Web Site for Europe

Standing Group of Experts on Lumpy Skin Disease in South-East Europe under the GF-TADs umbrella

**Presentation / objectives**

Lumpy Skin Disease is a growing concern in Europe, due to the recent spread in Israel (2012), Turkey (2013), Azerbaijan (July 2014), Russia (July 2015), Greece (August 2015) and further spread into the Balkans in the course of 2016 (Bulgaria).

A new initiative called *Standing Group of Experts on Lumpy Skin Disease in South East Europe* (hereafter referred to as "SGE-LSD") was launched on 4-5 July 2016 under the GF-TADs umbrella to build up a closer cooperation among countries affected by Lumpy Skin Disease (LSO) and thereby address the disease in a more collaborative and harmonised manner across the region.

This is a unique opportunity to engage affected countries into a fruitful regional dialogue and increased transparency. GF-TADs offers the ideal framework to discuss common / harmonised mitigation measures based on scientific grounds. LSO was discussed during the 6th meeting of the GF-TADs for Europe Steering Committee.

The Standing Group of Exporters LSD builds on the successful experience of the SGE-LSD. It will be a platform to discuss policies, tools and mitigation measures in close cooperation with the relevant authorities and the private sector.
Lumpy Skin Disease recent Activities (recent-ongoing)


- **Ministerial Conference on Lumpy Skin Disease** (8-9 Sep 2016, Sofia-Bulgaria)

- PAFF Committee, **new EU rules on LSD** to replace the ones currently in place (13-14 Sep 2016, Brussels)

- Appointment of **EU Reference Laboratory** for Diseases caused by Capripox viruses incl. LSD (Sep 2016)

- **Submission of LSD vaccination programmes** by EU Member States (either affected or not by LSD) for Commission assessment / approval
Lumpy Skin Disease Policy and Priorities

- LSD is a **regional problem** requiring international cooperation/coordination
- We need to be prepared for a **long and persistent fight** against the disease
- **Mass vaccination** coupled with **stamping out** is the most effective control measure (EFSA urgent advice on LSD, 9 Aug 2016)
- Each country, should **enhance preparedness and ensure efficient & timely procurement of sufficient vaccine doses** for the implementation of vaccination programmes
- We need to establish **special rules for LSD-free countries that implement vaccination as a precautionary measure**
- **OIE Code chapter on LSD currently being revised**
- **Further research** is needed on LSD (vectors, animal-to-animal transmission, DIVA vaccines, serological tests etc.)
European Union Lumpy Skin Disease Vaccine Bank

Created in April 2016 to support the initial stages of an LSD vaccination campaign

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of doses granted</th>
<th>Delivery date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulgaria</td>
<td>150,000</td>
<td>April 2016</td>
</tr>
<tr>
<td>Greece</td>
<td>100,000</td>
<td>April &amp; July 2016</td>
</tr>
<tr>
<td>the former Yugoslav Republic of Macedonia</td>
<td>50,000</td>
<td>May 2016</td>
</tr>
<tr>
<td>Serbia</td>
<td>50,000</td>
<td>June 2016</td>
</tr>
<tr>
<td>Kosovo*</td>
<td>25,000</td>
<td>July 2016</td>
</tr>
<tr>
<td>Albania</td>
<td>25,000</td>
<td>July 2016</td>
</tr>
<tr>
<td>Montenegro</td>
<td>25,000</td>
<td>July 2016</td>
</tr>
<tr>
<td>Croatia</td>
<td>50,000</td>
<td>Sep 2016</td>
</tr>
</tbody>
</table>

475,000 doses of LSD vaccine already granted to various countries
LSD vaccination – Situation as at Sep 2016

Vaccination completed in:
- Bulgaria
- Greece (Northern part)
- Serbia
- FYROM
- Montenegro

Vaccination in progress in:
- Albania
- Kosovo
- Croatia
- Southern part of continental Greece
LSD zoning (new LSD Decisions voted in PAFF 13-14 Sep 2016)

Free zones with Vaccination (Part I):
- Croatia
- Bulgaria (certain areas in the North and East part)

Infected zones (Part II):
- Continental Greece (including the island of Limnos)
- Bulgaria (excluding the "free with vaccination" zones)
LSD future activities - priorities

- **New EU decisions on LSD voted 12-13 Sep PAFF Standing Committee**
  (adoption expected for end of Oct-early Nov)

- **LSD vaccine bank:**
  Procedures for expansion – replenishment in progress

- **BTSF Regional Workshop on LSD**
  (for EU MS & South East European neighbours, 22-25 Nov 2016, Sofia-Bulgaria)

- **GF TADs: 3rd meeting of the Standing Group of Experts on Lumpy skin disease for South-East Europe - SGE LSD3**
  (12 and 13 December 2016, Istanbul-Turkey)

- **EFSA : request submitted by DG SANTE for updated epidemiological analysis of the LSD data (MS affected ±at risk & third countries )**
  (2 reports expected, Jan 2017 and Jan 2018)
Thank you for your attention!

**Acknowledgement:**
Dimitrios Dilaveris, SANTE G3, Policy Officer
Nadège Leboucq, OIE SRR Brussels, GF-TADs Europe secr.